algeldrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4250	21645-51-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aluminum hydroxide algeldrate aluminum hydroxide hydrate aluminium hydroxide	A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. Molecular weight: 78.00 Formula: AlH3O3 CLOGP: -1.75 LIPINSKI: None HAC: 3 HDO: 3 TPSA: 60.69 ALOGS: ROTB: 0

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aluminum hydroxide
algeldrate
aluminum hydroxide hydrate
aluminium hydroxide

A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.

Molecular weight: 78.00
Formula: AlH3O3
CLOGP: -1.75
LIPINSKI: None
HAC: 3
HDO: 3
TPSA: 60.69
ALOGS:
ROTB: 0

Drug dosage:

Dose	Unit	Route
5	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1983	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Schizoaffective disorder	253.11	19.57	51	2992	2155	50599926
Drug level increased	147.39	19.57	52	2991	19216	50582865
Electrocardiogram QT prolonged	106.39	19.57	55	2988	51831	50550250
Drug interaction	71.41	19.57	73	2970	199548	50402533
Delirium	37.07	19.57	25	3018	38167	50563914
Sinus rhythm	29.47	19.57	7	3036	633	50601448
Coma scale abnormal	25.82	19.57	10	3033	4761	50597320
Acute myocardial infarction	25.65	19.57	18	3025	29255	50572826
Morbid thoughts	25.33	19.57	6	3037	536	50601545
Hypercapnia	22.58	19.57	9	3034	4618	50597463
Hyponatraemia	20.47	19.57	27	3016	96112	50505969
Agitation	19.85	19.57	20	3023	53364	50548717

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mesothelioma	37.40	18.86	8	1968	405	29572146
Violence-related symptom	25.10	18.86	6	1970	501	29572050
IVth nerve paresis	21.02	18.86	3	1973	12	29572539

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myocardial infarction	37.11	18.56	32	3877	69686	64425137
Violence-related symptom	34.02	18.56	8	3901	687	64494136
Morbid thoughts	23.54	18.56	6	3903	720	64494103
Cardio-respiratory arrest	22.90	18.56	29	3880	98364	64396459
Mesothelioma	22.45	18.56	5	3904	337	64494486
Hypercapnia	21.13	18.56	10	3899	7684	64487139
Coma scale abnormal	21.03	18.56	10	3899	7764	64487059
Anal incontinence	19.74	18.56	12	3897	15184	64479639
Diabetic foot	18.73	18.56	7	3902	2998	64491825
Myeloid maturation arrest	18.68	18.56	3	3906	33	64494790
Seizure	18.64	18.56	35	3874	166857	64327966

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02AB01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Aluminium compounds
ATC	A02AB02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Aluminium compounds
MeSH PA	D000276	Adjuvants, Immunologic
MeSH PA	D000863	Antacids
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D007155	Immunologic Factors
CHEBI has role	CHEBI:65265	antacids
CHEBI has role	CHEBI:79314	flame retardants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Heartburn	indication	16331000
Duodenal ulcer disease	indication	51868009	DOID:1724
Indigestion	indication	162031009
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Gastric ulcer	indication	397825006	DOID:10808
Gastric Hypersecretory Conditions	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.51	acidic
pKa2	4.99	acidic
pKa3	5.47	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018607	VUID
N0000146920	NUI
D02807	KEGG_DRUG
4017984	VANDF
4018607	VANDF
4019302	VANDF
C0002371	UMLSCUI
CHEBI:33130	CHEBI
CHEMBL3833310	ChEMBL_ID
CHEMBL1200706	ChEMBL_ID
D000536	MESH_DESCRIPTOR_UI
1945	INN_ID
03J11K103C	UNII
66458	PUBCHEM_CID
DB06723	DRUGBANK_ID
612	RXNORM
4159	MMSL
5582	MMSL
7537	MMSL
d00978	MMSL
001123	NDDF
007943	NDDF
273944007	SNOMEDCT_US
725733004	SNOMEDCT_US
768557001	SNOMEDCT_US
80399002	SNOMEDCT_US
1330-44-5	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Good Sense antacid	HUMAN OTC DRUG LABEL	3	0113-0340	SUSPENSION	800 mg	ORAL	OTC monograph final	13 sections
Good Sense AntacidRegular Strength	HUMAN OTC DRUG LABEL	3	0113-0357	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Good Sense AntacidMaximum Strength	HUMAN OTC DRUG LABEL	3	0113-0588	SUSPENSION	800 mg	ORAL	OTC monograph final	13 sections
good sense antacid	HUMAN OTC DRUG LABEL	3	0113-0851	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Mag-AL Liquid	HUMAN OTC DRUG LABEL	2	0121-1760	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL Plus	HUMAN OTC DRUG LABEL	3	0121-1761	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL PlusXS	HUMAN OTC DRUG LABEL	3	0121-1762	SUSPENSION	400 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0094	LIQUID	95 mg	ORAL	OTC monograph final	13 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0095	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
GavisconRegular Strength	HUMAN OTC DRUG LABEL	2	0135-0096	TABLET, CHEWABLE	80 mg	ORAL	NDA	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0098	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0430	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0574	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
Antacid Mint	HUMAN OTC DRUG LABEL	3	0363-0432	SUSPENSION	200 mg	ORAL	OTC MONOGRAPH FINAL	14 sections
Antacid Mint	HUMAN OTC DRUG LABEL	3	0363-0432	SUSPENSION	200 mg	ORAL	OTC MONOGRAPH FINAL	14 sections
Antacid antigasMaximum Strength	HUMAN OTC DRUG LABEL	3	0363-0528	LIQUID	800 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	12 sections
ADVANCED REGULAR STRENGTH ANTACID	HUMAN OTC DRUG LABEL	3	0363-1639	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
MAXIMUM STRENGTH ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0363-1691	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
REGULAR STRENGTH ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0363-2628	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
Walgreens Fast Acting Heartburn Relief Extra Strength	HUMAN OTC DRUG LABEL	2	0363-7630	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
ALMACONE DOUBLE STRENGTH	HUMAN OTC DRUG LABEL	3	0536-0015	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
ALMACONE ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0536-0025	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
Aluminum Hydroxide	HUMAN OTC DRUG LABEL	1	0536-0091	LIQUID	320 mg	ORAL	OTC monograph final	10 sections
rugby almacone	HUMAN OTC DRUG LABEL	3	0536-1185	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Antacid	Human OTC Drug Label	3	0536-1293	LIQUID	400 mg	ORAL	OTC MONOGRAPH FINAL	12 sections
REGULAR STRENGTH ANTACID/ANTIGAS	HUMAN OTC DRUG LABEL	3	0536-1317	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
MAXIMUM STRENGTH ANTACID/ ANTIGAS	HUMAN OTC DRUG LABEL	3	0536-1318	SUSPENSION	800 mg	ORAL	OTC monograph final	10 sections
Almacone	HUMAN OTC DRUG LABEL	3	0536-3504	TABLET, CHEWABLE	200 mg	ORAL	OTC monograph final	12 sections
MI-ACID REGULAR STRENGTH	HUMAN OTC DRUG LABEL	3	0904-0004	SUSPENSION	200 mg	ORAL	OTC monograph final	9 sections